Ultragenyx Pharmaceutical Inc.

For the period ended Dec 31, 2025. Filed Feb 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 18, 2026

RARE$16.41+6.4%Stored close · as of Nov 9, 2026

Opening this filing…